[115]
In order to satisfy the
Sierra Club
test, Novopharm was required to identify and elaborate the documents and information that required protection. Rather than providing such elaboration, Novopharm chose to assert that everything in an ANDS is necessarily confidential. Prothonotary Milczynski rejected this approach on a Rule 151 motion, and I believe she was correct to do so.